Article

Moore named Iridex interim president, CEO

William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.

Mountain View, CA-William M. Moore has been named interim president and chief executive officer (CEO) of Iridex Corp. Moore succeeds Dominik Beck, whose employment with the company ceased Aug. 24.

Moore will continue to serve as chairman of the Iridex board of directors during his tenure as interim CEO. He has served as a director of the company since September 2007.

Moore co-founded Natus Medical Inc. in 1990 and served as CEO until 1993. He still serves on the Natus board of directors. Moore also served as a consultant to BlueLine Partners, a private equity firm and investor in Iridex, from February 2004 until June 2008.

Iridex also announced that the board has appointed James Mackaness as chief operating officer, effective immediately. He will continue to serve in his role as the company’s chief financial officer.

In assuming the president and CEO role, Moore indicated that he will lead Iridex’s strategic direction and execution to increase shareholder value, whereas Mackaness will assume more day-to-day operational responsibilities.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.